• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Options MD Raises $2.35M to Expand Virtual Care for Severe Depression

Share:

November 3, 2022

Options MD, a telehealth startup focused on severe depression, scooped up $2.35 million in a pre-seed funding round led by Bread & Butter Ventures.

Others participating in the raise include M13, Bright Ventures and Collab Capital alongside returning investors MedMountain Ventures and Techstars.

The startup has also received $100,000 from the Google for Startups Latino Founders Fund. The latest raise brings Options MD’s total pre-seed funding to nearly $4 million.

WHAT THEY DO

Options MD is currently focused on providing virtual care for treatment-resistant depression, when a patient’s symptoms don’t improve after trying two different types of antidepressants.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Patients first fill out a screening form about their depression, lifestyle and overall health to be accepted with Options MD. They can then participate in an intake session with a psychiatrist and access new treatments, which can range from talk therapy and new medications to transcranial magnetic stimulation (TMS) and ketamine.

The startup said it plans to use the funding from the pre-seed round to expand its clinical operations and research as well as improve its proprietary clinical protocols.

“Instead of being incentivized to only offer one or two treatments, at Options MD, we believe care should be comprehensive and personalized,” Morgan Hewett, cofounder of Options MD, said in a statement. “Through our virtual platform, we are nurturing one of the country’s largest communities for treatment-resistant depression. We are focused on providing high-touch, high-quality care for this historically difficult-to-treat patient population.”

MARKET SNAPSHOT

Although digital health funding has slumped this year compared with the massive investment seen in 2021, mental health continues to be a leading therapeutic area. According to a report by Rock Health, digital mental health companies have brought in $1.7 billion so far in 2022, and more startups are focusing on complex mental illnesses.

Another company that aims to manage patients with severe mental illness is Valera Health, which this week announced it had raised $44.5 million in growth equity financing.

Other startups offering virtual psychiatric care include Sensible Care, Iris Telehealth and Talkiatry.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Employee Health Company Kenzen Begins Partnership with Examinetics and Receives InvestmentEmployee Health Company Kenzen Begins Partnership with Examinetics and Receives Investment
  • Nines Banks $16.5m for Tele-radiology, Ai Imaging Triage PlatformNines Banks $16.5m for Tele-radiology, Ai Imaging Triage Platform
  • The Sky Remains the Limit for AbbVie with New Collaborative PartnershipsThe Sky Remains the Limit for AbbVie with New Collaborative Partnerships
  • Smart Bed Maker Sleep Number Adds New Features to Monitor HealthSmart Bed Maker Sleep Number Adds New Features to Monitor Health
  • Erbe Elektromedizin to Acquire Maxer Endoscopy.Erbe Elektromedizin to Acquire Maxer Endoscopy.
  • Octave Bioscience Scores $30M for Neurodegenerative Disease OfferingsOctave Bioscience Scores $30M for Neurodegenerative Disease Offerings
  • Mental Health App ThoughtFull, Pfizer to Expand Access to Biopsychosocial Care in SingaporeMental Health App ThoughtFull, Pfizer to Expand Access to Biopsychosocial Care in Singapore
  • Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan PearlCullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications